Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026).

Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) turned in stellar performances in 2018. Abbott's shares jumped 27%, while DexCom stock more than doubled. It's a different story so far this ...

It’s buff versus buffet in the latest DTC ad battle of continuous glucose monitors. While Dexcom continues its blood-sugar monitoring campaign with musician and heartthrob Nick Jonas, Abbott takes a ...